C075P: Etanercept Biosimilar

Catalog No.: C075P | **Product Name:** Etanercept Biosimilar

Etanercept Biosimilar. The research grade etanercept biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls and recombinant hIgG1 Fc proteins are available.

PRODUCT SPECIFICATIONS

Catalog No.	C075P
Product Name	Etanercept Biosimilar
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	TNF Inhibitor, Tumor Necrosis Factor Alpha Inhibitor
Summary	Recombinant Fusion Protein of Soluble TNF Receptor 2 and Human IgG1 Fc.
Isotype / Construct	TNFR2-Fc Fusion Protein (Human IgG1 Fc).
Source/Host	The etanercept biosimilar protein was produced in the Enbrel biosimilar CHO stable cell line.
Specificity/Sensitivity	The etanercept biosimilar protein specifically binds to the human TNF alpha.
Applications	Functional assays, and those assays for studying biological pathways affected by etanercept.
Form Of Antibody	0.2 μM filtered solution, pH 7.1 to 7.7, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade etanercept biosimilar protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade etanercept biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls and recombinant hIgG1 Fc proteins are available.

REFERENCES & BACKGROUND

What is research grade Etanercept biosimilar? Research grade Etanercept biosimilar has the same amino acid sequence as Etanercept (trade name Enbrel), a fusion protein of the soluble TNF receptor 2 and a Fc fragment (human IgG1 isotype). Etanercept can be used to treat autoimmune diseases by interfering with tumor necrosis factor (TNF), a soluble inflammatory cytokine, by acting as a TNF inhibitor. TNF alpha is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF alpha. Etanercept binds to TNF alpha and decreases its role in disorders involving excess inflammation in humans and other animals, including autoimmune diseases such as ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and, potentially, in a variety of other disorders mediated by excess TNF alpha.